Innovotech Inc. (TSXV: IOT; OTCQB: IOTCF), an Edmonton-based life sciences services company specialising in applied microbiology, analytical chemistry, and regulated laboratory services, reported its third-quarter 2026 financial results on November 10, 2026. The company reduced its net loss by 40% from the prior quarter to $390,335, or $0.01 per share, while gross margin improved sharply to 29.8% from 8.6% in Q2. Investors may be watching the company's regulated testing growth and newly secured credit facilities as signals of operational stabilisation.

Key Points

  • Innovotech Inc. (TSXV: IOT; OTCQB: IOTCF) — Edmonton-based applied microbiology and regulated laboratory services company
  • Q3 2026 net loss narrowed 40% quarter-over-quarter to $390,335; September alone recorded a net loss of approximately $24,000
  • GMP, analytical chemistry, and stability testing revenue reached $363,112, up 9% year-over-year; working capital stood at $712,523 with a current ratio of 2.28
  • ATB Financial committed a $500,000 revolving operating facility and $100,000 corporate credit card facility, accepted October 29, 2026

Cost Restructuring Drives Margin Recovery Across Innovotech's Laboratory Operations

Innovotech's cost-reduction actions taken earlier in 2026 produced measurable results in the third quarter. Total costs before grants and tax credits fell 22% from Q2 to $1.11 million, while general and administrative expenses decreased 24% to $413,276. Gross margin recovered to 29.8% from 8.6% the previous quarter, though the company acknowledged margins remain below what it believes the business can sustain. Revenue held steady at $661,762. The company noted that because changes continued through September, the full benefit of its leaner cost base is expected to be more completely reflected in Q4 2026.

Regulated Testing Services Represent More Than Half of Innovotech's Revenue

GMP, analytical chemistry, and stability testing services posted their strongest quarter of 2026, generating $363,112 — a 9% increase from Q3 2025 and 13% from Q2 2026. These regulated services now account for more than half of total company revenue and serve a broad client base spanning pharmaceutical, biotechnology, healthcare, and industrial sectors. The release states the growth reflects consistent customer service and infrastructure investments, including additional equipment and clean room capacity for GMP-associated sterility testing. The company operates through ISO-certified and GMP-accredited laboratories.

InnovoTEST™ Launch and ATB Financial Facilities Strengthen Innovotech's Growth Platform

Innovotech launched InnovoTEST™ hazardous drug wipe testing kits in August 2026, targeting pharmacies, hospitals, and cancer centres. On November 3, 2026, the company signed a distribution agreement with Healthmark, described as a coast-to-coast Canadian distributor, to extend InnovoTEST™ into hospital, community, and long-term care pharmacies nationwide. Separately, on October 29, 2026, ATB Financial committed a $500,000 revolving operating facility and a $100,000 corporate credit card facility. The company is consolidating its banking with ATB to simplify operations and reduce costs, according to the release.